BR112014019480A8 - Composto fumarato de morfolinoalquila,composição farmacêutica,e,uso dos mesmos - Google Patents

Composto fumarato de morfolinoalquila,composição farmacêutica,e,uso dos mesmos

Info

Publication number
BR112014019480A8
BR112014019480A8 BR112014019480A BR112014019480A BR112014019480A8 BR 112014019480 A8 BR112014019480 A8 BR 112014019480A8 BR 112014019480 A BR112014019480 A BR 112014019480A BR 112014019480 A BR112014019480 A BR 112014019480A BR 112014019480 A8 BR112014019480 A8 BR 112014019480A8
Authority
BR
Brazil
Prior art keywords
morpholinoalkyl
pharmaceutical composition
fumarate compound
disease
fumarates
Prior art date
Application number
BR112014019480A
Other languages
English (en)
Other versions
BR112014019480A2 (pt
Inventor
C Cundy Kenneth
K Manthati Suresh
J Wustrow David
Original Assignee
Xenoport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport Inc filed Critical Xenoport Inc
Publication of BR112014019480A2 publication Critical patent/BR112014019480A2/pt
Publication of BR112014019480A8 publication Critical patent/BR112014019480A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings

Abstract

COMPOSTO FUMARATO DE MORFOLINOALQUILA, COMPOSIÇÃO FARMACÊUTICA, E, USO DOS MESMOS. Fumaratos de morfolinoalquila, composições farmacêuticas que compreendem os fumaratos de morfolinoalquila e métodos de usar os fumaratos de morfolinoalquila e composições farmacêuticas para tratar distúrbios neurodegenerativos, inflamatórios e autoimunes incluindo esclerose múltipla, psoríase, distúrbio do intestino irritado, colite ulcerativa, artrite, doença pulmonar obstrutiva crônica, asma, doença de Parkinson, doença de Huntington e esclerose lateral amiotrófica são descritos.
BR112014019480A 2012-02-07 2013-02-07 Composto fumarato de morfolinoalquila,composição farmacêutica,e,uso dos mesmos BR112014019480A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261595835P 2012-02-07 2012-02-07
PCT/US2013/025118 WO2013119791A1 (en) 2012-02-07 2013-02-07 Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use

Publications (2)

Publication Number Publication Date
BR112014019480A2 BR112014019480A2 (pt) 2017-06-20
BR112014019480A8 true BR112014019480A8 (pt) 2017-07-11

Family

ID=47720772

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014019480A BR112014019480A8 (pt) 2012-02-07 2013-02-07 Composto fumarato de morfolinoalquila,composição farmacêutica,e,uso dos mesmos

Country Status (15)

Country Link
US (2) US8952006B2 (pt)
EP (1) EP2812319A1 (pt)
JP (1) JP5918395B2 (pt)
KR (1) KR20140129136A (pt)
CN (1) CN104169261A (pt)
AU (1) AU2013203335B2 (pt)
BR (1) BR112014019480A8 (pt)
CA (1) CA2864040A1 (pt)
IL (1) IL233941A0 (pt)
MX (1) MX2014009511A (pt)
NZ (1) NZ629728A (pt)
RU (1) RU2014136394A (pt)
TW (1) TWI486339B (pt)
WO (1) WO2013119791A1 (pt)
ZA (1) ZA201406145B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2477884T3 (es) 2008-08-19 2014-07-18 Xenoport, Inc. Profármacos de hidrogenofumarato de metilo, composiciones farmacéuticas de los mismos y procedimientos de uso
EP2854795A1 (en) * 2012-05-30 2015-04-08 XenoPort, Inc. Treatment of multiple sclerosis and psoriasis using prodrugs of methyl hydrogen fumarate
CA2882713A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
WO2014031897A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Oral dosage forms having a high loading of (n,n- diethylcarbamoyl)methyl methyl|(2e)but-2-ene-1,4-dioate
US20140057918A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of Use for Monomethyl Fumarate and Prodrugs Thereof
ES2733961T3 (es) * 2012-12-21 2019-12-03 Biogen Ma Inc Derivados de fumarato sustituidos con deuterio
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
DK2970101T3 (en) * 2013-03-14 2018-08-20 Alkermes Pharma Ireland Ltd PRO-DRUGS OF FUMARATES AND THEIR USE IN TREATING DIFFERENT DISEASES
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
TW201516020A (zh) 2013-09-06 2015-05-01 Xenoport Inc （ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途
EP3049074A1 (en) * 2013-09-27 2016-08-03 ratiopharm GmbH Prodrugs of monomethyl fumarate (mmf)
WO2015082590A2 (en) * 2013-12-05 2015-06-11 Ratiopharm Gmbh Bis-mmf derivatives
CA2940845C (en) * 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US9944669B2 (en) 2014-03-21 2018-04-17 Universite Paris Est Creteil Val De Marne Fumarate-CO-releasing molecule hybrids, their use in the treatment of inflammatory or cardiovascular diseases and their process of preparation
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
US10170537B2 (en) 2014-12-23 2019-01-01 International Business Machines Corporation Capacitor structure compatible with nanowire CMOS
US9630934B2 (en) * 2015-02-08 2017-04-25 Mark Quang Nguyen Fumarate compounds, pharmaceutical compositions thereof, and methods of use
CN107847475A (zh) 2015-05-28 2018-03-27 贝勒医学院 补充n‑乙酰半胱氨酸和甘氨酸以改善谷胱甘肽水平的有益效果
CN111065619B (zh) * 2017-08-29 2022-08-12 浙江海正药业股份有限公司 (E)-α,β-不饱和酰胺化合物及其制备方法和用途
CN116307280B (zh) * 2023-05-18 2023-08-01 成都理工大学 一种酸性气藏气井储层硫堵损伤量化评估方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2163060A1 (de) * 1971-12-18 1973-06-20 Basf Ag Waesserige dispersionen von mischpolymerisaten von monoestern olefinisch ungesaettigter dicarbonsaeuren
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19814358C2 (de) 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DE19839566C2 (de) 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
PL392748A1 (pl) 2001-01-12 2011-05-09 Fumapharm Ag Amidy kwasu fumarowego
DE10101307A1 (de) 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
DE10217314A1 (de) 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
GB0320441D0 (en) * 2003-09-02 2003-10-01 Givaudan Sa Organic compounds
ES2297461T3 (es) 2003-09-09 2008-05-01 Fumapharm Ag Uso de derivados del acido fumarico para tratar la insuficiencia cardiaca y el asma.
DE10342423A1 (de) 2003-09-13 2005-04-14 Heidland, August, Prof. Dr.med. Dr.h.c. Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden
ES2523796T1 (es) 2004-10-08 2014-12-01 Forward Pharma A/S Composición farmacéutica de liberación controlada que comprende éster de ácido fumárico
US20080004344A1 (en) 2004-11-10 2008-01-03 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
DE102005022845A1 (de) 2005-05-18 2006-11-23 Fumapharm Ag Thiobernsteinsäurederivate und deren Verwendung
US20080299196A1 (en) 2005-10-07 2008-12-04 Aditech Pharma Ab Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
CN101304732A (zh) * 2005-10-07 2008-11-12 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
EP2019671B1 (en) 2006-05-05 2014-09-24 The Regents Of The University Of Michigan Intermediates for the preparation of bivalent smac mimetics
ES2477884T3 (es) * 2008-08-19 2014-07-18 Xenoport, Inc. Profármacos de hidrogenofumarato de metilo, composiciones farmacéuticas de los mismos y procedimientos de uso
WO2011085211A1 (en) * 2010-01-08 2011-07-14 Catabasis Pharmaceuticals, Inc. Fatty acid fumarate derivatives and their uses
WO2014096425A2 (en) 2012-12-21 2014-06-26 Ratiopharm Gmbh Prodrugs of monomethyl fumarate (mmf)

Also Published As

Publication number Publication date
US20130203753A1 (en) 2013-08-08
MX2014009511A (es) 2014-10-24
KR20140129136A (ko) 2014-11-06
CA2864040A1 (en) 2013-08-15
EP2812319A1 (en) 2014-12-17
ZA201406145B (en) 2016-06-29
US8952006B2 (en) 2015-02-10
IL233941A0 (en) 2014-09-30
JP2015508073A (ja) 2015-03-16
CN104169261A (zh) 2014-11-26
RU2014136394A (ru) 2016-03-27
BR112014019480A2 (pt) 2017-06-20
TWI486339B (zh) 2015-06-01
NZ629728A (en) 2016-07-29
AU2013203335A1 (en) 2013-08-22
US20140051705A1 (en) 2014-02-20
AU2013203335B2 (en) 2016-05-26
TW201343634A (zh) 2013-11-01
JP5918395B2 (ja) 2016-05-18
WO2013119791A1 (en) 2013-08-15

Similar Documents

Publication Publication Date Title
BR112014019480A8 (pt) Composto fumarato de morfolinoalquila,composição farmacêutica,e,uso dos mesmos
EA201400729A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ СОДЕРЖАТ ГЛИТАЗОНЫ И Nrf2 АКТИВАТОРЫ
CL2016001947A1 (es) Compuestos derivados de dihidropirrolopiridina, inhibidores de ror-gamma (ror); composición farmacéutica; y uso en el tratamiento de asma, enfermedad pulmonar obstructiva crónica, artritis reumatoide, fibrosis quística, psoriasis, epilepsia, alzheimer, entre otras.
CL2016001706A1 (es) Compuestos de nicotinamida sustituida con heteroarilo
CL2016001516A1 (es) Reguladores nrf2.
SV2015005019A (es) Anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorios
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
CO2018009889A2 (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
CL2014000314A1 (es) Compuestos derivados de ciclopropanamina, inhibidores de desmetilasa especifica de lisina 1 (lsd1); medicamento que los comprende; metodo para profilaxis o tratamiento; metodo para inhibir lsd1; y su uso en la profilaxis o tratamiento de esquizofrenia, enfermedad de alzheimer, enfermedad de parkinson o corea de huntington.
CL2015002301A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxílico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c.
BR112014027165A2 (pt) antagonistas de st2l e métodos de uso
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
EA201690501A1 (ru) Новые композиции для лечения неврологических расстройств
BR112015023827A2 (pt) composições de limpeza contendo uma poliéter amina
BR112015023001A8 (pt) composições resultantes da retirada de exons para o tratamento de distrofia muscular.
BR112015023038A2 (pt) composições para salto de exon para o tratamento da distrofia muscular
CL2013001340A1 (es) Compuestos derivados de isoindol-amida, pirrolo-piridin-amida y pirrolo-pirimimidin-amida, inhibidores de nampt y rock; composicion farmaceutica; y metodo para tratar hiperetension, insuficiencia cardiaca cronica, aterosclerosis, asma, enfermedad de alzheimer, enfermedad de parkinson y glaucoma, entre otras enfermedades.
BR112018009050A2 (pt) mananases de paenibacillus e bacillus spp.
CL2013001604A1 (es) Compuestos derivados de pirimidinona sustituida; composicion farmaceutica que los comprende; su uso para tratar la enfermedad de alzheimer y la aterosclerosis.
BR112016026512A2 (pt) Processo para a produção de alquenóis e uso dos mesmos para a produção de 1,3-butadieno
CR20160394A (es) Heteroaril amidas como inhibidores de agregación de proteína
BR112014016389A8 (pt) composições e uso das mesmas para o tratamento de distúrbios e doenças hepáticas
WO2014197818A8 (en) Small molecule activators of nrf2 pathway
RS54584B1 (en) 15-HEPE PREPARATIONS AND PROCEDURES FOR THEIR USE
CL2012001143A1 (es) Anticuerpo anti-fractalkina (anti-fkn); composicion farmaceutica que comprende dicho anticuerpo anti-fkn; acido nucleico; vector; celula huesped; uso del anticuerpo anti-fkn para tratar trastornos inflamatorios.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]